Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).

Authors

Douglas W. Blayney

Stanford University, Stanford, CA

Douglas W. Blayney , Alice Kate Cummings Joyner , John Jarvis , Dominic Nunag , Jasmine Wells , Lan Huang , Ramon W. Mohanlal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Association of primary prophylactic (PP) granulocyte-colony stimulating factor (G-CSF) use with chemotherapy dose modifications and relative dose intensity (RDI) among breast cancer patients receiving high-risk regimens for febrile neutropenia (FN).

First Author: Jaime Shaw

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer.

First Author: Roopa Lakhanpal

insert_chart_outlined

Poster

2020 ASCO Quality Care Symposium

bookmark_border

Cost-effectiveness of filgrastim-sndz as primary prophylaxis (PP) versus secondary prophylaxis (SP) to prevent chemotherapy-induced febrile neutropenia (FN) in breast cancer patients at intermediate risk.

First Author: Edward C. Li

insert_chart_outlined

Poster

2012 Breast Cancer Symposium

bookmark_border

Adjuvant docetaxel and cyclophosphamide (DC) with prophylactic growth colony stimulating factor (GCSF) on days 8 and 12 in breast cancer patients: A retrospective analysis.

First Author: Rinat Yerushalmi